CD274 and cancer: Prospective clinical trials such as the phase II trial studying the efficacy of Nivolumab and Ipilimumab in patients with rare cancers (NCT02834013) are currently enrolling patients with CD274 amplifications, defined as at least 6 copies of CD274 detected through CGP.